Ckd Bio (063160) — Capital Reinvestment Ratio
Latest as of June 2025:
0.56x
Ckd Bio (063160) has a Capital Reinvestment Ratio of 0.56x as of June 2025, meaning it reinvests 1% of its operating cash flow (₩3.19 Billion) in capital expenditures (₩1.80 Billion). See debt-free asset ratio of Ckd Bio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
0.56x
Capex / Operating Cash Flow
Operating Cash Flow
₩3.19 Billion
KRW
Capital Expenditures
₩1.80 Billion
KRW
Data as of
Jun 2025
Most recent filing
Ckd Bio Capital Reinvestment Ratio (2008–2024)
This chart tracks Ckd Bio's Capital Reinvestment Ratio across 14 annual periods. Check Ckd Bio total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Ckd Bio (2008–2024)
Year-by-year Capital Reinvestment Ratio for Ckd Bio from 2008 to 2024. For live market cap and broader valuation context, see 063160 market cap.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.31x | ₩14.03 Billion | ₩4.28 Billion | ▼ -97.6% |
| 2020 | 12.78x | ₩4.82 Billion | ₩61.66 Billion | ▲ +359.0% |
| 2019 | 2.78x | ₩16.99 Billion | ₩47.31 Billion | ▲ +163.9% |
| 2018 | 1.06x | ₩15.54 Billion | ₩16.40 Billion | ▲ +123.1% |
| 2017 | 0.47x | ₩20.45 Billion | ₩9.67 Billion | ▼ -31.8% |
| 2016 | 0.69x | ₩15.50 Billion | ₩10.76 Billion | ▼ -16.5% |
| 2015 | 0.83x | ₩14.34 Billion | ₩11.91 Billion | ▲ +225.1% |
| 2014 | 0.26x | ₩11.22 Billion | ₩2.87 Billion | ▼ -31.9% |
| 2013 | 0.38x | ₩10.92 Billion | ₩4.10 Billion | ▲ +56.7% |
| 2012 | 0.24x | ₩22.90 Billion | ₩5.48 Billion | ▼ -86.0% |
| 2011 | 1.70x | ₩12.96 Billion | ₩22.09 Billion | ▲ +106.2% |
| 2010 | 0.83x | ₩23.89 Billion | ₩19.74 Billion | ▲ +62.3% |
| 2009 | 0.51x | ₩26.57 Billion | ₩13.53 Billion | ▲ +56.8% |
| 2008 | 0.32x | ₩10.69 Billion | ₩3.47 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow